Recurrent Adult Immunoblastic Large Cell Lymphoma Active Not Recruiting Phase 2 Trials for Alemtuzumab (DB00087)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00040846Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesTreatment
NCT00118352Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerTreatment